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ABSTRACT
OBJECTIVE
To determine outcomes and safety of endovascular 
treatment for acute ischaemic stroke, due to 
proximal intracranial vessel occlusion in the anterior 
circulation, in routine clinical practice.
DESIGN
Ongoing, prospective, observational cohort study.
SETTING
16 centres that perform endovascular treatment in the 
Netherlands.
PARTICIPANTS
1488 patients included in the Multicentre Randomised 
Controlled Trial of Endovascular Treatment for Acute 
Ischaemic Stroke in the Netherlands (MR CLEAN) 
Registry who had received endovascular treatment, 
including stent retriever thrombectomy, aspiration, 
and all alternative methods for acute ischaemic stroke 
within 6.5 hours from onset of symptoms between 
March 2014 and June 2016.
MAIN OUTCOME MEASURES
The primary outcome was the modified Rankin Scale 
(mRS) score, ranging from 0 (no symptoms) to 6 
(death) at 90 days after the onset of symptoms. 
Secondary outcomes were excellent functional 
outcome (mRS score 0-1), good functional outcome 
(mRS score 0-2), and favourable functional outcome 
(mRS score 0-3) at 90 days; score on the extended 
thrombolysis in cerebral infarction scale at the end 
of the intervention procedure; National Institutes 
of Health Stroke Scale score 24-48 hours after 
intervention; and complications that occurred during 
intervention, hospital admission, or three months’ 
follow up period. Outcomes and safety variables in the 
MR CLEAN Registry were compared with the MR CLEAN 
trial intervention and control arms.
RESULTS
A statistically significant shift was observed towards 
better functional outcome in patients in the MR 
CLEAN Registry compared with the MR CLEAN trial 
intervention arm (adjusted common odds ratio 1.30, 
95% confidence interval 1.02 to 1.67) and the MR 
CLEAN trial control arm (1.85, 1.46 to 2.34). The 
reperfusion rate, with successful reperfusion defined 
as a score of 2B-3 on the extended thrombolysis 
in cerebral infarction score, was 58.7%, the same 
as for patients in the MR CLEAN trial. Duration from 
onset of stroke to start of endovascular treatment 
and from onset of stroke to successful reperfusion or 
last contrast bolus was one hour shorter for patients 
in the MR CLEAN Registry. Symptomatic intracranial 
haemorrhage occurred in 5.8% of patients in the MR 
CLEAN Registry compared with 7.7% in the MR CLEAN 
trial intervention arm and 6.4% in the MR CLEAN trial 
control arm.
CONCLUSION
In routine clinical practice, endovascular treatment 
for patients with acute ischaemic stroke is at least as 
effective and safe as in the setting of a randomised 
controlled trial.
Introduction
Endovascular treatment for acute ischaemic stroke, due 
to proximal intracranial vessel occlusion in the anterior 
circulation, has been shown to be effective and safe in 
several randomised controlled trials and subsequent 
meta-analyses.1-9 In the Multicentre Randomised 
Controlled Trial of Endovascular Treatment for Acute 
Ischaemic Stroke in the Netherlands (MR CLEAN) good 
functional outcome was clearly more often reached 
with endovascular treatment (33%) than without 
(19%).2 In the pooled analysis of individual patient 
data of the first five randomised controlled trials 
with positive results, the number needed to treat to 
reduce disability was 2.6.9 However, these results were 
achieved within the confines of randomised controlled 
trials with strict inclusion and exclusion criteria. The 
MR CLEAN trial had the most broadly defined inclusion 
criteria of these randomised controlled trials, bearing 
in mind that doctor judgment most likely played a 
role in patient enrolment. Still, external validity of 
results acquired in randomised trials is always a point 
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WhAT IS AlReAdy knoWn on ThIS TopIC
Several randomised trials and meta-analyses have shown efficacy and safety of 
endovascular treatment for acute ischaemic stroke due to proximal intracranial 
vessel occlusion in the anterior circulation, within six hours from symptom onset
Whether outcomes and safety in routine clinical practice are comparable to 
previous randomised clinical trials of endovascular treatment for acute ischaemic 
stroke is unknown
Current information about outcomes and safety of endovascular treatment is 
derived from patients treated in the setting of a randomised controlled trial
WhAT ThIS STudy AddS
The results of the MR CLEAN Registry show that in routine clinical practice, 
endovascular treatment for patients with acute ischaemic stroke due to proximal 
intracranial vessel occlusion in the anterior circulation is at least as effective and 
safe as in the setting of a randomised controlled trial
The findings confirm that endovascular treatment should be standard of care 
for patients with acute ischaemic stroke due to proximal intracranial vessel 
occlusion in the anterior circulation
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of concern, as optimistic results might arise from 
selective inclusion, strict monitoring of procedures, 
and early termination.10 11
Currently, endovascular treatment has become 
the standard of care in many countries. In the 
Netherlands, the implementation of endovascular 
treatment as standard treatment for patients with 
acute ischaemic stroke due to proximal intracranial 
vessel occlusion is monitored in the MR CLEAN 
Registry. We determined outcomes and safety of 
endovascular treatment in routine clinical practice 
by comparing outcomes (clinical, imaging, and time 
characteristics) of patients in the MR CLEAN Registry 
with those in the MR CLEAN trial.
Methods
Design
The MR CLEAN Registry is an ongoing, prospective, 
observational study in all centres that perform 
endovascular treatment in the Netherlands. Until 
1 January 2017, endovascular treatment for acute 
ischaemic stroke was only reimbursed in the Netherlands 
if patients were treated in centres that participated in the 
MR CLEAN trial or the MR CLEAN Registry. All centres 
that participated in the MR CLEAN trial registered 
patients who received endovascular treatment, and we 
invited new intervention centres in the Netherlands 
performing endovascular treatment to participate.
Patient enrolment
Enrolment in the MR CLEAN Registry started directly 
after the final randomisation in the MR CLEAN trial on 
16 March 2014. From 16 March 2014 to 31 December 
2014 this was done retrospectively. From January 2015 
onwards, enrolment was prospective. Sixteen centres 
participated in the MR CLEAN trial and are considered 
“MR CLEAN centres.” Two non-MR CLEAN centres 
started performing endovascular treatment later on 
and added patients to the MR CLEAN Registry, but these 
patients are not included in this analysis. The study 
data for patients undergoing endovascular treatment 
up to 15 June 2016 in the 16 MR CLEAN centres were 
completed and analysed and are reported here.
All patients undergoing endovascular treatment 
(defined as entry into the angiography suite and 
receiving arterial puncture) for acute ischaemic 
stroke in the anterior and posterior circulation 
have been registered in the MR CLEAN Registry. To 
adequately compare results with the MR CLEAN trial, 
in the current analysis we included those patients who 
adhered to the following criteria: arterial puncture 
within 6.5 hours of symptom onset, age 18 years 
and older, treatment in a centre that participated in 
the MR CLEAN trial, and proximal intracranial vessel 
occlusion in the anterior circulation (internal carotid 
artery (ICA), internal carotid artery terminus (ICA-T), 
middle (M1/M2) cerebral artery, or anterior (A1/A2) 
cerebral artery), shown by computed tomography 
angiography, magnetic resonance angiography, or 
digital subtraction angiography. No upper age limit, 
minimum Alberta Stroke Program Early Computed 
Tomography Score (ASPECTS), or collateral grade were 
imposed on treating doctors, nor was an extracranial 
occlusion by atherosclerosis or dissection an exclusion 
criterion.
Outcomes
The primary outcome was the modified Rankin Scale 
(mRS) score,12 which was assessed as part of usual care 
for all patients with stroke in all centres. The mRS score 
is a common measure of patient functional outcome 
after stroke, ranging from 0 (no symptoms) to 6 (death). 
Study staff were instructed to assess mRS scores at 90 
days (range 14 days either way). Secondary outcomes 
were excellent functional outcome (mRS score 0-1), 
good functional outcome (mRS score 0-2), and 
favourable functional outcome (mRS score 0-3) at 90 
days (range 14 days either way); score on the extended 
thrombolysis in cerebral infarction scale at the end 
of the intervention procedure; National Institutes of 
Health Stroke Scale (NIHSS) score 24-48 hours after 
intervention; and complications that occurred during 
intervention, hospital admission, or the three months’ 
follow up period.
We obtained relevant images (baseline non-
contrast computed tomography, baseline computed 
tomography angiography, interventional digital 
subtraction angiography, and follow-up imaging), 
which were stored in an imaging database (XNAT; 
Neuroinformatics Research Group, St Louis, MO) and 
subsequently analysed by an imaging core laboratory.
Intervention procedure
Endovascular treatment consisted of arterial 
catheterisation with a micro-catheter to the level of 
occlusion, followed by mechanical thrombectomy or 
thrombus aspiration, or both, with or without delivery 
of a thrombolytic agent. The method of endovascular 
treatment for each patient was left to the discretion of 
the treating doctors.
Study procedures
Patients were registered through a website (www.
mrclean-trial.org/). Registrations were sent by encrypted 
email to the trial office. The trial office then matched 
patient data with a specific study identification number. 
Using this number, all data were entered into a good 
clinical practice approved, web based clinical database 
(OpenClinica Community version: 3.12.2). The study 
coordinators (IGHJ, MJHLM and RBG) checked all centre 
data for completeness, formatting, and consistency. 
The study coordinators verified sample source data 
for all entered data. To check on reporting of safety, 
we screened discharge letters for complications. For 
patients transferred from a referring stroke centre to an 
intervention centre, we collected clinical and imaging 
data from the referring stroke centre.
Imaging assessment
Twenty one observers (20 interventional 
neuroradiologists and one interventional neurologist) 
at an imaging core laboratory assessed the images. 
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The observers were blinded to all clinical findings, 
with the exception of clinical assessment of the 
occlusion location in case of baseline non-contrast 
computed tomography, and were assigned a random 
subset of images to assess. Before assessment 
began the observers were provided with guidelines 
including relevant definitions. In separate sessions, 
the observers evaluated ASPECTS on baseline non-
contrast computed tomography13; occluded arterial 
segment, clot burden score,14 and collateral score15 
on baseline computed tomography angiography; 
extended thrombolysis in cerebral infarction on 
digital subtraction angiography16; and presence of 
intracranial haemorrhage on follow up non-contrast 
computed tomography.17
ASPECTS is graded from 0 to 10, with 1 point 
subtracted from 10 for any evidence of early ischaemic 
changes in each defined region on non-contrast 
computed tomography.13 We graded collaterals on a 
4 point scale, with 0 for absent collaterals (0% filling 
of the vascular territory downstream of the occlusion), 
1 for poor collaterals (>0% and ≤50% filling of the 
vascular territory downstream of the occlusion), 2 for 
moderate collaterals (>50% and <100% filling of the 
vascular territory downstream of the occlusion), and 3 
for excellent collaterals (100% filling of the vascular 
territory downstream of the occlusion).15 The extended 
thrombolysis in cerebral infarction score ranges from 
0 (no antegrade reperfusion of the occluded vascular 
territory) to 3 (complete antegrade reperfusion of the 
occluded vascular territory).16 The score includes grade 
2C (slow flow in a few distal cortical vessels or presence 
of small distal cortical embolisms, corresponding to 
90-99% reperfusion). To reach a score of 2B or higher, 
it was mandatory to complete digital subtraction 
angiography runs including anteroposterior and 
lateral views after endovascular treatment. If a lateral 
view was missing, 2A was the highest possible score. 
We classified intracranial haemorrhage on follow-up 
imaging according to the Heidelberg criteria.17
Safety measures
The complication committee, consisting of two 
vascular neurologists and one neuroradiologist, 
evaluated the safety variables on the basis of discharge 
letters and reports from the imaging core laboratory. To 
prevent underreporting, one independent investigator 
(RBG) searched the medical records for complications. 
The safety variables included mortality within 7, 30, 
and 90 days of endovascular treatment, symptomatic 
intracranial haemorrhage, hemicraniectomy, 
progression of ischaemic stroke (resulting in a decline 
of at least 4 points on the NIHSS), pneumonia, 
other infections, cardiac ischaemia, extracranial 
haemorrhage, and allergic reactions.
We deemed intracranial haemorrhage to be 
symptomatic if patients died or deteriorated 
neurologically (a decline of at least 4 points on the 
NIHSS) and the haemorrhage was related to the clinical 
deterioration (according to the Heidelberg criteria). 
To minimise biased reporting, the imaging core 
laboratory analysed the follow-up images of patients 
with symptomatic intracranial haemorrhage, and the 
complication committee made the final decision for 
reporting a symptomatic intracranial haemorrhage. 
The complication committee evaluated the progression 
of ischaemic stroke and new ischaemic stroke on the 
basis of medical reports of admission.
Missing data
We retrospectively scored missing NIHSS scores 
using a standard score chart based on the reported 
information on neurological examination. If successful 
reperfusion was not achieved during endovascular 
treatment, we used the time of last contrast bolus 
injection as a proxy. Any mRS score of 0 to 5 assessed 
within 30 days of symptom onset was considered 
invalid and treated as missing. These values were 
therefore replaced by mRS scores derived from multiple 
imputation for the purpose of unbiased estimation of 
associations of outcome with baseline characteristics 
and comparisons with MR CLEAN results.18 All 
baseline data and outcomes that are reported are 
crude and not imputed. We performed multiple 
imputation with Stata/SE 14.2 (StataCorp, TX) using 
the variables: age, baseline NIHSS score, glucose level, 
diabetes, previous myocardial infarction, previous 
stroke, hypercholesterolemia, atrial fibrillation, 
drug use (antiplatelet, statin, coumarine, novel oral 
anticoagulant, and antihypertensive), prestroke mRS 
score, blood pressure, baseline ASPECTS, occlusion 
segment, collateral status, time from symptom onset 
to start of endovascular treatment, time from symptom 
onset to successful reperfusion or last contrast bolus, 
extended thrombolysis in cerebral infarction score at 
the end of the intervention, and NIHSS score after 24-
48 hours.
Study organisation
The intervention centres participating in the MR CLEAN 
trial enrolled patients who received endovascular 
treatment in the MR CLEAN Registry from the start, 
after closure of the MR CLEAN trial, and onwards. Local 
principal investigators were always a senior vascular 
neurologist and an interventionist. The local principal 
investigators together formed the steering committee, 
which met annually and was the final authority on 
changes to protocol.
The MR CLEAN trial
The MR CLEAN trial was a multicentre clinical trial 
with randomised treatment group assignments, which 
ran from December 2010 to March 2014. This trial 
compared endovascular treatment plus usual care 
with usual care alone (control group) in patients with 
acute ischaemic stroke and a proximal intracranial 
vessel occlusion in the anterior circulation that was 
confirmed on imaging.2 19
Statistical analysis
Baseline characteristics are described using standard 
statistics. We used regression models to compare 
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baseline characteristics and outcomes in patients 
in the MR CLEAN Registry with those in the MR 
CLEAN intervention and control arms. The effect of 
endovascular treatment on the mRS score at 90 days in 
patients in the MR CLEAN Registry compared with the 
MR CLEAN trial was expressed as an adjusted common 
odds ratio, derived from multivariable ordinal logistic 
regression (shift analysis). Because there is consensus 
on the ordering of the outcome scale in this case (each 
score on the mRS is more favourable than a 1 point 
lower score), the common odds ratio can be presented 
and interpreted as a summary estimate of the 
treatment effect, even if the underlying proportional 
odds assumption would be violated.20 Therefore, we 
decided not to formally test this assumption. For all 
outcome regression analyses using the mRS score, we 
used the score after multiple imputation. We adjusted 
for age, sex, baseline NIHSS score, prestroke mRS 
score, and collateral status. Statistical analyses were 
performed with Stata/SE 14.2 (StataCorp, TX).
Patient involvement
No patients were involved in setting the research 
question or the outcome measures, nor were they 
involved in developing plans for recruitment, design, 
or implementation of the study. No patients were asked 
to advise on interpretation or writing up of results. 
There are no plans to disseminate the results of the 
research to study participants or the relevant patient 
community.
Results
Overall, 1628 patients were registered in the MR 
CLEAN Registry between 16 March 2014 and 15 
June 2016. For the current analysis, we excluded 140 
patients, mostly because of occlusion in the posterior 
circulation or treatment starting after 6.5 hours from 
the onset of symptoms (see supplementary figure 
S1). Therefore 1488 patients were available for final 
analysis.
Participant characteristics
Overall, data on 26 259 of 26 784 of the 18 clinical and 
radiological baseline characteristics were complete 
(98.0%). The median age of patients was 71 years 
(interquartile range 60-80 years), and the median 
baseline NIHSS score was 16 (interquartile range 11-
20; table 1). Intravenous alteplase was administered 
to 1161 patients (78.0%), and 808 patients (54.3%) 
were transferred from a referring stroke centre 
to an intervention centre. The median time from 
onset of symptoms to start of intravenous alteplase 
treatment was 80 minutes (interquartile range 62-
120 minutes); from onset of symptoms to start of 
endovascular treatment was 208 (interquartile range 
160-265) minutes; and from onset of symptoms to 
successful reperfusion or last contrast bolus was 267 
(interquartile range 217-331) minutes. Most patients 
had occlusion of a middle cerebral artery (M1) (n=825; 
58.0%), followed by an internal carotid artery terminus 
occlusion (ICA-T) (n=313; 22.0%), and M2 occlusion 
(n=175; 12.3%). Ninety five patients (6.5%) had poor 
ASPECTS (0-4) on baseline non-contrast computed 
tomography, and 565 patients (40.9%) had absent or 
poor collaterals on baseline computed tomography 
angiography.
Major differences in baseline characteristics between 
patients in the MR CLEAN Registry and those in the MR 
CLEAN trial intervention arm were age (71 v 66 years), 
intravenous alteplase treatment (78.0% v 87.1%), 
prestroke mRS score >2 (11.7% v 4.3%), transfer from 
a referring stroke centre (54.4% v 44.2%), onset to 
start of endovascular treatment (208 v 260 minutes), 
and onset to successful reperfusion or last contrast 
bolus (267 v 339 minutes).
Intervention characteristics
In 80 of the 1488 patients (5.4%) the target occlusion 
was not accessible, mostly because of an elongated 
carotid artery or aortic arch, or an occlusion or stenosis 
of the carotid artery that could not be passed. In 119 
patients (8.0%), no target occlusion was present on 
digital subtraction angiography due to spontaneous 
reperfusion or distal migration of the clot beyond 
the M2 or anterior cerebral artery (A2 segment). 
Intravenous alteplase was administered in 108 out of 
119 patients (90.8%) and therefore possibly caused 
migration or dissolvement of the thrombus before 
endovascular treatment. In nine patients (0.6%), 
the local interventionist ended the procedure before 
thrombectomy was attempted, despite the presence 
of a target occlusion. Reasons for this were clinical 
recovery of the patient (n=3), vessel rupture (n=1), 
expiration of the six hour time window (n=1), and 
unknown (n=4). Of the 1280 patients (86.0%) in 
whom thrombus retrieval was attempted, the primary 
treatment modality was registered in 1220 (95.3%): 
stent retriever (n=969; 79.4%), aspiration device 
(n=207; 17.0%), local delivery of a thrombolytic 
agent (n=10; 0.8%), or a different approach (n=34; 
2.8%). A second treatment option was used in 314 of 
these 1220 (25.7%) patients and a third in 52 (4.3%) 
patients. The median duration of the procedure was 64 
minutes (interquartile range 40-90). In 810 of 1488 
patients (54.4%) only local anaesthesia at the groin 
puncture site was given. General anaesthesia was used 
in 379 patients (25.5%) and conscious sedation in 173 
patients (11.6%). Data on anaesthetic management 
were missing for 126 patients (8.5%).
Primary outcome
The mRS score was obtained for all 1488 patients, and 
multiple imputation was performed in 125 patients 
(8.4%) in whom the mRS score was assessed within 
30 days (see supplementary figure S2), because of 
the lower reliability of this early assessment in a 
hospital setting. Of the imputed variables, 33 111 of 
the 34 224 (96.7%) were complete. After adjustment 
for age, sex, baseline NIHSS score, collateral status, 
and pre-stroke mRS score, the shift towards better 
functional outcome was significant for patients in the 
MR CLEAN Registry compared with those in the MR 
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CLEAN intervention arm (adjusted common odds ratio 
1.30, 95% confidence interval 1.02 to 1.67; P=0.03) 
and control arm (1.85, 1.64 to 2.34; P<0.01; fig 1). The 
corresponding unadjusted values were 1.05 (0.83 to 
1.32) and 1.49 (1.19 to 1.85). These associations were 
similar when data without imputations were analysed 
(see supplementary table S3).
Secondary outcomes
In the MR CLEAN Registry, good functional outcome 
(mRS score 0-2) was achieved in 517 of 1363 patients 
(37.9%; table 2), compared with 32.6% in the MR 
CLEAN intervention arm and 19.1% in the control arm. 
The NIHSS score at 24-48 hours after endovascular 
treatment was available in 1274 of the 1400 (91.0%) 
patients who were still alive. For these patients, the 
median NIHSS score was 11 (interquartile range 4-17; 
table 2), and for 236 patients (16.9%) the NIHSS score 
was 2 or lower. On average, the NIHSS score improved 
by 4 points (interquartile range 0-9) between baseline 
and 24-48 hours after stroke onset. Compared with 
patients in the MR CLEAN trial intervention and 
control arms those in the MR CLEAN Registry achieved 
statistically significantly better scores for all secondary 
outcomes, with the exception of successful reperfusion 
(see supplementary table S1).
Since the time from onset of symptoms to start of 
endovascular treatment was shorter in patients in 
Table 1 | Characteristics at baseline of patients in MR CLEAN Registry and MR CLEAN trial (intervention and control arms). Values are numbers 
(percentages) of participants unless stated otherwise
Characteristics
MR CLEAN Registry  
(n=1488)
MR CLEAN
Intervention arm (n=233) Control arm (n=267)
Median (interquartile range) age (years) 71 (60-80) 66 (55-76) 66 (56-76)
Men 794 (53.3) 135 (57.9) 157 (58.8)
Median (interquartile range) NIHSS score 16 (11-20) 17 (14-21) 18 (14-22)
Clinical localisation: left hemisphere 745 (53.5) 116 (49.8) 153 (57.3)
Mean (SD) systolic blood pressure (mm Hg) 150 (25) 146 (26) 145 (24)
Intravenous alteplase treatment 1161 (78.0) 203 (87.1) 242 (90.6)
Medical history:
 Atrial fibrillation 327 (22.3) 66 (28.3) 69 (25.8)
 Hypertension 745 (50.7) 98 (42.1) 129 (48.3)
 Diabetes mellitus 255 (17.2) 34 (14.6) 34 (12.7)
 Myocardial infarction 228 (15.6) 33 (14.2) 42 (15.7)
 Peripheral artery disease 135 (9.3) 8 (3.4) 16 (6.0)
 Ischaemic stroke 249 (16.8) 29 (12.4) 25 (9.4)
Prestroke modified Rankin Scale score:
 0 991 (67.8) 190 (81.6) 214 (80.2)
 1 189 (12.9) 21 (9.0) 29 (10.9)
 2 110 (7.5) 12 (4.9) 13 (5.2)
 ≥3 171 (11.7) 10 (4.3) 11 (4.1)
Current smoking 338 (22.9) 65 (27.9) 78 (29.2)
Drug use:
 Statin 522 (35.8) 65 (27.9) 78 (29.2)
 Antiplatelet 493 (33.6) 64 (27.5) 80 (30.0)
Level of occlusion on non-invasive vessel imaging:
 ICA 82 (5.7) 1 (0.4) 3 (1.1)
 ICA-T 313 (22.0) 59 (25.3) 75 (28.2)
 M1 825 (58.0) 154 (66.1) 165 (62.0)
 M2 175 (12.3) 18 (7.7) 21 (7.9)
 Other* 27 (1.9) 1 (0.4) 2 (0.8)
ASPECTS subgroups:
 0-4 93 (6.5) 10 (4.7) 19 (7.2)
 5-7 341 (24.0) 54 (23.3) 39 (14.8)
 8-10 989 (69.5) 167 (72.0) 206 (78.0)
Collaterals grade:
 0 97 (7.0) 9 (3.9) 17 (6.5)
 1 461 (33.3) 72 (30.7) 64 (24.3)
 2 535 (38.7) 88 (38.1) 110 (42.2)
 3 288 (20.9) 62 (27.3) 71 (27.0)
Transfer from primary stroke centre 808 (54.4) 118 (44.2) 101 (43.4)
Categories after onset of stroke (median (interquartile range)):
 To intravenous alteplase treatment (mins) 80 (62-120) 85 (67-110) 87 (65-116)
 To intervention centre (mins) 134 (60-189) 90 (48-186) 104 (49-209)
 To endovascular treatment (mins) 208 (160-265) 260 (210-313) NA
  Median (interquartile range) to successful reperfusion or last contrast bolus (mins) 267 (217-331) 339 (274-395) NA
ICA=internal carotid artery; ICA-T=internal carotid artery terminus; M1/M2=middle cerebral artery; NA= not applicable.
*In nine patients the occlusion location was considered to be in the middle cerebral artery (M2) at the moment endovascular treatment was decided, but the imaging core laboratory observed 
an M3 occlusion. Six patients had a proximal occlusion in the anterior cerebral artery (A1/A2). Twelve patients underwent endovascular treatment without a definitive occlusion on computed 
tomography angiography according to the core laboratory.
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the MR CLEAN Registry compared with those in the 
MR CLEAN trial intervention arm, we did additional 
analysis adjusting for this variable. This resulted in 
a smaller treatment effect and also in the absence 
of a statistically significant difference in functional 
outcome between patients in the MR CLEAN Registry 
and those in the MR CLEAN trial intervention arm 
(adjusted common odds ratio 1.11, 95% confidence 
interval 0.86 to 1.43; P=0.43). The two studies also 
showed clear differences between baseline systolic 
blood pressure and treatment with intravenous 
alteplase. Additional adjustments for these two factors 
increased the effect of endovascular treatment in 
patients in the MR CLEAN Registry compared with 
those in the MR CLEAN trial intervention and control 
arms (see supplementary table S4).
Of all patients analysed, 1467 (98.6%) had an 
extended thrombolysis in cerebral infarction score 
available after intervention. Successful reperfusion 
was achieved in 849 of 1467 patients (57.9%). In the 
1280 cases in which an actual endovascular treatment 
device was used, reperfusion status (extended 
thrombolysis in cerebral infarction score) was available 
for 1266 patients (98.9%). In the remaining 14 patients 
(1.1%), intervention images were unavailable or of 
insufficient quality, and no extended thrombolysis 
in cerebral infarction score was ascertained. Of 
these 1266 patients with extended thrombolysis in 
cerebral infarction scores, 743 (58.7%) had successful 
reperfusion (score 2B: n=239; score 2C: n=125; and 
score 3: n=379; table 2). For 199 patients (15.7%), a 
lateral digital subtraction angiography projection after 
treatment was not obtained, and 2A was the highest 
achievable score.
In patients without imputed mRS scores, death 
within 90 days occurred in 398 of 1363 (29.2%) 
in the MR CLEAN Registry compared with 21.0% 
and 22.1% in MR CLEAN intervention and control 
arms, respectively (table 3 and supplementary table 
S2). In 86 out of 1488 patients (5.8%) symptomatic 
intracranial haemorrhage occurred compared with 
7.7% and 6.4% in the MR CLEAN intervention and 
control arms, respectively. The MR CLEAN Registry was 
comparable to the MR CLEAN trial intervention and 
control arms for mortality, symptomatic intracranial 
haemorrhage, and almost all other complications. 
Only hemicraniectomy and progression of ischaemic 
stroke occurred less often in patients in the MR CLEAN 
Registry.
discussion
The results of our study show that endovascular 
treatment in routine clinical practice, for patients 
recorded in the MR CLEAN Registry with acute 
ischaemic stroke, due to proximal intracranial vessel 
occlusion in the anterior circulation, is at least as 
effective and safe as in the MR CLEAN trial. A higher 
proportion of patients reached good functional 
outcome after 90 days, despite older age and more 
comorbidities. Times from stroke onset to start of 
endovascular treatment and from onset to successful 
reperfusion or last contrast bolus improved in patients 
in the MR CLEAN Registry compared with those in the 
MR CLEAN trial, and comparable reperfusion rates 
were achieved.
Limitations of this study
The MR CLEAN Registry is a large, consecutive, 
nationwide study, representative of current clinical 
Percentage
MR CLEAN
Registry
(n=1363)
MR CLEAN trial
(intervention arm,
n=233)
MR CLEAN trial
(control arm,
n=267)
0 20 40 60 80 100
0
mRS scores
1 2 3 54 6
6% 13% 19% 14% 29%14% 5%
3% 9% 21% 18% 21%22% 6%
6% 13% 16% 22%30% 12%
Fig 1 | Distribution of modified Rankin Scale (mRS) score 
at 90 days in MR CLEAN Registry (before imputation) 
and MR CLEAN trial intervention and control arms. 
The proportion of deaths is calculated as 398 of 1363 
patients instead of 1488 patients and therefore inflated 
by 2% because in this figure the denominator does not 
include 125 patients with missing mRS scores. The mRS 
category 0 for the MR CLEAN control arm is small (n=1, 
0.4%) and therefore not visible in the figure
Table 2 | Primary and secondary outcomes of MR CLEAN Registry and MR CLEAN trial intervention and control arms. Values are numbers (percentages) 
of participants unless stated otherwise
Scores MR CLEAN Registry (n=1488)*
MR CLEAN
Intervention arm (n=233) Control arm (n=267)
Median (interquartile range) mRS score at 90 days 3 (2-6) 3 (2-5) 4 (3-5)
mRS score at 90 days
 0-1 258 (18.9) 27 (11.6) 16 (6.0)
 0-2 517 (37.9) 76 (32.6) 51 (19.1)
 0-3 710 (52.1) 119 (51.1) 95 (35.6)
Successful reperfusion (eTICI grade 2B-3)† 743/1266 (58.7) 115/196 (58.7) NA
Median (interquartile range) NIHSS score post-intervention (24 hours) 11 (4-17) 13 (6-20) 16 (12-21)
mRS=modified Rankin Scale; eTICI=extended thrombolysis in cerebral infarction; NA=not applicable; NIHSS=National Institutes of Health Stroke Scale.
*Of 1363 patients without imputed mRS scores.
†In patients where an actual endovascular treatment device was used and reperfusion status assessed.
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practice, and with core laboratory evaluation of all 
images and complications. However, there were still 
several limitations. Firstly, inherent to a registry 
study, non-registration of treated patients might 
be problematic. As registration of treatment was a 
prerequisite for reimbursement, we think that under-
registration is minimal. Secondly, no central outcome 
adjudication was available for our study, so we relied on 
local investigators for reporting the functional outcome 
at 90 days, possibly introducing bias. Optimistic 
reports from local investigators could have resulted in a 
larger proportion of functionally independent patients. 
However, stroke or research nurses not involved 
in the treatment of patients primarily performed 
outcome assessment, and according to standard 
questionnaires. Thirdly, not all digital subtraction 
angiography images were of sufficient quality for 
optimal assessment of successful reperfusion, because 
sometimes full anteroposterior or lateral runs were not 
available. This probably resulted in underreporting 
of successful reperfusion, as a maximum score of 
extended thrombolysis in cerebral infarction 2A could 
be achieved in those cases. Fourthly, we report data 
from the Netherlands only. Extrapolation of our results 
to other countries should be done with caution, taking 
into account differences in logistics, experience and 
technical expertise of interventionists, local guidelines, 
and availability of resources. Our broad entry criteria 
could, however, enhance the generalisability. Finally, 
patients with ischaemic stroke due to occlusion of 
an intracranial proximal artery were not registered 
in the database if they did not undergo endovascular 
treatment. Consequently, we are unaware of the reason 
why endovascular treatment was not performed 
in these patients. Patient selection bias based on a 
changed clinical status, or patient characteristics such 
as comorbidity and being of an older age group (>80 
years old), could have occurred. However, this is one 
of the few studies in which a relatively large number of 
patients with absent or poor collaterals were treated, 
which emphasises that patients with poor prognostic 
factors were not systematically excluded from 
endovascular treatment.
Since the widespread implementation of 
endovascular treatment as standard of care in the 
Netherlands, two studies describing outcomes of 
endovascular treatment in routine clinical practice 
have been published. The first included 77 patients 
with ischaemic stroke in the anterior circulation.21 The 
second was a multicentre registry, which prospectively 
enrolled 984 patients with any confirmed large vessel 
occlusion (including in the posterior circulation), 
without other prespecified imaging selection.22 
Consecutive inclusion was not required. Treatment 
had to be started within eight hours after the onset 
of symptoms. Good functional outcome (mRS score 
0-2) was achieved in 56.5%, successful reperfusion 
(extended thrombolysis in cerebral infarction score 
2B-3) in 87.9%, and symptomatic intracranial 
haemorrhage within 24 hours in 1.4% of patients. 
However, in contrast with the MR CLEAN Registry, no 
patients with prestroke functional dependency were 
enrolled, patients were slightly younger, and inclusion 
was restricted to patients with baseline NIHSS scores 
of 8 or more or 30 or less, which might reduce the 
degree to which these results represent current routine 
clinical practice. Moreover, patients had to be treated 
with a thrombectomy device (Solitaire or Mindframe) 
from one company, whereas in the MR CLEAN Registry 
this was left to discretion of the interventionist.
Despite consistent proportions of patients who 
experienced successful reperfusion in the MR CLEAN 
Registry and the MR CLEAN trial, the improved 
functional outcome in patients in the MR CLEAN 
Registry can be explained by a shorter time from 
onset of symptoms to successful reperfusion or last 
contrast bolus of more than one hour. After additional 
adjustment for this variable, the difference in benefit 
of endovascular treatment between the MR CLEAN 
Registry and the MR CLEAN trial intervention arm 
decreased and was no longer statistically significant. 
This again emphasises the importance of decreasing 
time from symptom onset to start of endovascular 
treatment as well as procedure times. Faster successful 
reperfusion might also have contributed to the lower 
rates of hemicraniectomy and stroke progression 
Table 3 | Overview of complications in MR CLEAN Registry and MR CLEAN trial intervention and control arms. Values are 
numbers (percentages) of participants
Complications MR CLEAN Registry (n=1488)
MR CLEAN
Intervention arm (n=233) Control arm (n=267)
Mortality:
 7 days 207 (15.2)* 33 (14.2) 27 (10.1)
 30 days 328 (24.1)* 44 (18.9) 49 (18.4)
 90 days 398 (29.2)* 49 (21.0) 59 (22.1)
Symptomatic intracranial haemorrhage 86 (5.8) 18 (7.7) 17 (6.4)
Hemicraniectomy 32 (2.2) 14 (6.0) 13 (4.9)
Progression of ischaemic stroke 140 (9.4) 46 (19.7) 47 (17.6)
Pneumonia 184 (12.3) 25 (10.7) 41 (15.4)
Other infection 75 (5.0) 16 (6.9) 9 (3.4)
Cardiac ischaemia 12 (0.8) 1 (0.4) 4 (1.5)
Extracranial haemorrhage 33 (2.2) 0 2 (0.8)
Allergic reaction 10 (0.7) 1 (0.4) 0
Other complications 213 (14.1) 22 (9.4) 33 (12.4)
*Of 1363 patients without imputed modified Rankin Scale scores.
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in patients in the MR CLEAN Registry. Increased 
experience of the interventionists could also have 
contributed to the rate of good functional outcome 
in routine clinical practice. Finally, the proportion of 
patients who died within 90 days of onset of symptoms 
was higher than those in the MR CLEAN trial. This 
could be explained by a broader population being 
considered for endovascular treatment in routine 
clinical practice, including patients of greater age and 
prestroke morbidity.
The results of our study might have important 
implications for the future of endovascular treatment 
for acute ischaemic stroke. We found that in routine 
clinical practice, endovascular treatment started within 
6.5 hours after stroke onset shows results comparable 
to the trial setting (we chose to extend the time window 
by a half hour compared with that in the MR CLEAN trial, 
to be compatible with the trial inclusion criterion of 
intended treatment within six hours). These outcomes 
are reported in a broad group of patients without 
imaging selection (apart from computed tomography 
angiography to confirm occlusion of proximal vessels), 
in contrast with the trend in current clinical trials to 
select patients before treatment with a favourable 
prognosis based on imaging characteristics. However, 
some patient selection probably also occurred in this 
registry, because treatment decisions were made based 
on individual considerations by doctors.
The MR CLEAN Registry elucidates that, despite 
much research over the past years, patient selection 
for endovascular treatment is still not applied in a 
structured manner in clinical practice, at least in 
the Netherlands. Despite this, patients’ functional 
outcome improved substantially compared with 
the MR CLEAN trial. Research is needed to improve 
existing patient selection paradigms and tools, 
particularly those combining clinical and imaging 
variables,23 and to provide consensus on how patient 
selection for endovascular treatment can be reliably 
and consistently implemented.
Conclusion
In routine clinical practice, endovascular treatment 
for patients with acute ischaemic stroke, due to 
proximal intracranial vessel occlusion in the anterior 
circulation, is at least as effective and safe as in the 
setting of a randomised controlled trial.
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